Search

everythinglearnresearchcommunity

for

Search:↓

Scientists at UCLA have developed a promising treatment for male pattern baldness using a molecule called PP405, which can potentially stimulate dormant hair follicles. Initial trials showed significant results within a week, but larger clinical trials are needed to confirm its efficacy and safety.

The user experienced hair regrowth after 5 months on 5 mg oral minoxidil and 1 mg dutasteride, following a year of ineffective finasteride use. They noticed progress after an initial shedding phase and hope for further improvement, with expectations of near-max regrowth around 18 months.

Clascoterone in Winlevi, a topical AR antagonist, is being re-examined due to concerns about HPA axis suppression in adolescents, but it's unlikely to be banned for adult use in androgenetic alopecia (AGA). The European Medicines Agency recommended refusing Winlevi for acne vulgaris, but this may not affect Breezula's approval for AGA.

PP405 shows promise for hair regrowth, with new hairs observed in 66% of patients in just 27 days. The discussion also mentions Minoxidil, finasteride, and RU58841 as potential treatments.

PP405 shows initial promise for treating androgenetic alopecia, with safety confirmed in early trials, but skepticism remains due to limited data. Further trials are needed to determine its true efficacy and potential market impact.

The user has been using a combination spray of finasteride, minoxidil, and tretinoin for 5 months, along with microneedling and biotin, and is uncertain about hair regrowth progress. Other users suggest more time is needed for results, with peak results at 2 years, and mention oral dutasteride as an effective treatment.

A user's 5 month progress with their hair loss treatment which includes topical finasteride and minoxidil, microneedling once every 10 days, and keto shampoo twice a week. Other users shared their own experiences and advice on treatments.

A user's 5-month progress with Finasteride 1mg for hair loss, which is showing promising results; other users have suggested adding additional treatments such as Minoxidil and Derma Rolling to further boost regrowth.

A 33-year-old male has been using topical dutasteride and minoxidil twice daily, along with a 0.25 mm derma roller every five days, and is experiencing hair shedding but seeing progress. Some users suspect a hair transplant, while others praise the results.

P5P supplementation helped reverse finasteride side effects, particularly by lowering prolactin levels and restoring sensitivity. The user experienced significant improvement within a day and full recovery in a few days.

The user experienced significant hair regrowth after 5 months of using 0.5 mg dutasteride and 5 mg minoxidil daily. They reported no major side effects except for reduced libido.

A user shared their 5-month hair regrowth progress using 0.5mg Dutasteride daily and 5% Minoxidil foam twice daily, reporting significant improvement despite initial shedding. Other users discussed their experiences with similar treatments, noting varied results and side effects, with some emphasizing the need for long-term commitment to maintain hair growth.

Fatty acid metabolic signaling can activate epithelial stem cells for hair regeneration. Oleic and palmitoleic acids showed the best results, but practical application on humans remains uncertain.

The user has been using Minoxidil and finasteride with success and is now trying Dualgen-5R with retinoic acid but without finasteride, along with microneedling. They plan to share results in 5-6 months.

A 19-year-old concerned about long-term effects of 5AR inhibitors on physical appearance. They have used finasteride and plan to try dutasteride or RU58841; responses suggest improved skin, hair, and confidence.

PP405 is considered a potential new treatment for hair loss, compared to finasteride and minoxidil. There is skepticism about its effectiveness in humans, with anticipation for more information from an upcoming conference.

The conversation discusses alternatives to 5AR inhibitors for hair loss treatment, suggesting options like minoxidil, KX-826, pyrilutimide, microneedling, and topical bicalutamide. Concerns about side effects and the effectiveness of these treatments are also highlighted.

PP405 targets hair follicle stem cells differently than exercise-induced lactate, suggesting exercise alone may not replicate its benefits. Minoxidil and finasteride are recommended alongside exercise for hair regrowth, with additional suggestions like spicy food and infrared exposure.

The user reported solid results after 5 months of using 1.25mg finasteride daily, with minimal sexual side effects and some hair regrowth at the hairline. They discontinued minoxidil due to its greasy effect on their hair.

Dutasteride is associated with increased blood glucose, HbA1c, LDL cholesterol, and liver enzyme activity, potentially leading to diabetes, NAFLD, and liver metabolism changes. The conversation highlights concerns about these adverse effects and calls for more studies, including on finasteride.

A user's experience of using Fin, Min and Microneedle treatments to help thicken their hair before undergoing a Hair Transplant (HT) procedure. The conversation also includes discussion about the results post-HT, including pictures.

User is using a homemade topical treatment with .015% finasteride, 5% minoxidil, and microneedling at .75mm depth. They also use 2% ketoconazole shampoo, various oils, and are considering increasing finasteride concentration due to mixed results.

The user has been using finasteride and minoxidil for 5 years to prevent hair loss and is considering adding dutasteride for regrowth or opting for a hair transplant. Suggestions include trying dutasteride, oral minoxidil, microneedling, and possibly a hair transplant for better results.

The conversation discusses Fevipiprant, an asthma drug that may block CRTH2 and potentially stop male pattern baldness (MPB) without inhibiting DHT. It also mentions the use of finasteride and dutasteride for hair loss.

GT20029 showed significant hair growth and safety in phase II trials, with no adverse sexual events. Users are hopeful but concerned about future costs and systemic effects.

Dutasteride is more effective than finasteride for hair loss, especially at the crown and midscalp, but both have similar side-effect profiles with low incidence of sexual adverse events. Improvement is measured visually, and significant results may take over 12 months to appear.

A user shared their 5-month progress using topical minoxidil and finasteride for hair loss. Others congratulated and suggested a haircut style.

A new hair loss treatment, PP405, is moving from phase 2A to 2B in clinical trials, sparking discussions about its potential to regrow dormant hairs and its impact on existing treatments like Minoxidil and finasteride. Some users express skepticism, while others are hopeful about its future effectiveness.

The user shared their 5-month progress using oral finasteride, topical minoxidil, and weekly dermarolling for hair loss. They expressed pride in their results, receiving positive feedback from others.

A 25-year-old switched from finasteride to dutasteride, experiencing significant hair regrowth and improved hair quality after 6 months, taking it three times a week. The user stopped finasteride entirely, citing dutasteride's longer half-life as more effective.